2.2. Participants and Data Sources
TSGH, allergic reactions, breast cancer
ALLERGIC REACTION, BREAST CANCER
This was a randomized, interventional clinical study that enrolled patients undergoing breast cancer surgery between August 1, 2018, and December 31, 2018, in Tri-Service General Hospital, Taipei, Taiwan. The study protocol was approved by the Institutional Review Board of our hospital (TSGH IRB No: 2–107-05-079) and registered in the ClinicalTrial.gov database (NCT03817359). Participants were recruited with written informed consent obtained in the ward the day before surgery, after being provided with detailed information. Inclusion criteria were American Society of Anesthesiologists (ASA) grades II to III, age >18 y, and being scheduled for breast cancer surgery under TIVA. Exclusion criteria included previously determined allergic reactions to propofol or remifentanil, and the performance of other surgical procedure in the same session leading to extended operative time of > 1 h. Patients were randomly and equally assigned to two groups (separate, S group; mixed, M group) using computer-generated random numbers. All operations were conducted by the same surgeon (JC Yu), and all anesthesia was performed by one single anesthesiologist (ZF Wu). The data were recorded by a nurse anesthetist who was blinded. In addition, cases and the operator were blinded. 